Health Care·Biotechnology·$2.7B
Veracyte Inc (VCYT) is a biotechnology company focused on improving patient outcomes through genomic diagnostics. Their innovative tests help in the early detection and diagnosis of various cancers and other diseases, making them significant in the healthcare sector as demand for precision medicine grows.
EPS
Earnings per share is a key indicator of profitability and performance, reflecting how much profit is allocated to each share of stock.
Revenue
Revenue is crucial for understanding the company's sales performance and growth trajectory, especially in the competitive biotech industry.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+363.36%
Avg Stock Reaction
+0.33%
In the last quarter, Veracyte reported an impressive EPS of $0.53, significantly beating estimates. The stock reacted positively, reflecting investor confidence in the company's growth.
Management Promises & Guidance
Analysts expect Veracyte to report strong earnings, continuing a trend of positive surprises. The consensus is optimistic about revenue growth driven by new product launches.
Bull Case
If Veracyte meets or exceeds EPS and revenue estimates, it could signal strong demand for their products and further market share gains, potentially driving the stock higher.
Bear Case
Conversely, any miss on earnings or revenue could raise concerns about market competition and product adoption, leading to a negative reaction in the stock.
EPS
$0.33Earnings per share is a key indicator of profitability and performance, reflecting how much profit is allocated to each share of stock.
Revenue
$130MRevenue is crucial for understanding the company's sales performance and growth trajectory, especially in the competitive biotech industry.
The print will turn on these two things.
Q1
Will Veracyte achieve an EPS of at least $0.33?
This figure is critical as it sets the benchmark for investor expectations and reflects the company's profitability.
Q2
How does Veracyte's revenue compare to the expected $130M?
Revenue performance will indicate the effectiveness of their product strategies and market demand.
Why consensus could be wrong
The Street may underestimate Veracyte's ability to leverage recent product innovations, which could drive stronger-than-expected revenue growth.
Supporting Evidence
Veracyte's history of exceeding EPS estimates suggests a potential for continued strong performance.
The options market is pricing a larger move than historical averages, indicating heightened expectations.
Recent product launches may not be fully reflected in consensus estimates.
Key Risk
If revenue comes in below $127M, it could challenge the bullish outlook and raise concerns about market dynamics.
Pre-commit to what would confirm each case.
The upcoming earnings report is pivotal as it will either reinforce the company's growth narrative or raise concerns about its market position.
Bull Confirmed If
Achieving an EPS of $0.37 or higher would confirm the bull case, indicating strong operational performance.
Bear Confirmed If
An EPS below $0.23 would support the bear case, suggesting potential issues with product uptake or market competition.
Implied Move
±10.23%
Historical Avg
±1.6%
The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings announcement.
Options are pricing ±10.2% while VCYT has averaged ±1.6% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Veracyte beats expectations, history suggests a potential average one-day move of +0.33%, confirming strong market demand.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical data suggesting an average one-day drop when expectations are not met.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026